An Engineered Biopolymer Prevents Mucositis Induced by 5-Fluorouracil in Hamsters

American Journal of Pathology

Volumn 164, Issue 2, 2004, Pages 739-746

  Morvan, Frédéric O ^a   Baroukh, Brigitte ^a   Ledoux, Dominique ^b   Caruelle, Jean Pierre ^b   Barritaul, Denis ^b   Godeau, Gaston ^a   Saffar, Jean Louis ^a,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Université Paris 12 ^*  (France)

^c Faculte de Chirurgie Dentaire   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOPOLYMER; FLUOROURACIL; GELATINASE A; GELATINASE B; PLASMIN; RG 1503; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; OLIGOSACCHARIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; BIOENGINEERING; BLOOD CELL COUNT; BODY WEIGHT; CHEEK MUCOSA; CONNECTIVE TISSUE; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; CYTOTOXICITY; DRUG INDUCED DISEASE; HAMSTER; JEJUNUM; MOUTH MUCOSA; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; MALE; PATHOLOGY; STOMATITIS; SYRIAN HAMSTER; WESTERN BLOTTING;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BASEMENT MEMBRANE; BIOPOLYMERS; BLOTTING, WESTERN; CRICETINAE; FLUOROURACIL; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MESOCRICETUS; MOUTH MUCOSA; OLIGOSACCHARIDES; STOMATITIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 1542289715     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63161-6     Document Type: Article

References (32)

1. Clarke J, Butler R, Howarth G, Read L, Regester G: Exposure of oral mucosa to bioactive milk factors reduces severity of chemotherapy-induced mucositis in the hamster. Oral Oncol 2002, 38:478-485
2. NIH Consensus Statement: National Institutes of Health consensus development conference statement: oral complications of cancer therapies: diagnosis, prevention, and treatment. J Am Dent Assoc 1989, 119:179-183
3. Sonis ST: Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 1998, 34:39-43
4. Loury DJ, Embree JR, Steinberg DA, Sonis ST, Fiddes JC: Effect of local application of the antimicrobial peptide IB-367 on the incidence and severity of oral mucositis in hamsters. Oral Surg Oral Med Oral Pathol 1999, 87:544-551
5. Sonis ST, Peterson RL, Edwards LJ, Lucey CA, Wang L, Mason L, Login G, Yamakawa M, Moses G, Bouchard P, Hayes LL, Bedrosian C, Dorner AJ: Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol 2000, 36:373-381
6. Plevova P: Prevention and treatment of chemotherapy- and radiotherapy-induced oral mucositis: a review. Oral Oncol 1999, 35:453-470
7. Escartin Q, Lallam-Laroye C, Baroukh B, Morvan FO, Caruelle JP, Godeau G, Barritault D, Saffar JL: A new approach to treat tissue destruction in periodontitis with heparan mimetics. EMBO J 2003, 17:644-651
8. Meddahi A, Lemdjabar H, Caruelle JP, Barritault D, Hornebeck W: FGF protection and inhibition of human neutrophil elastase by carboxymethyl benzylamide sulfonate dextran derivatives. Int J Biol Macromol 1996, 18:141-145
9. Ledoux D, Papy-Garcia D, Escartin Q, Sagot MA, Cao Y, Barritault D, Courtois J, Hornebeck W, Caruelle JP: Human plasmin enzymatic activity is inhibited by chemically modified dextrans. J Biol Chem 2000, 275:29383-29390
10. Ledoux D, Merciris D, Barritault D, Caruelle JP: Heparin-like dextran derivatives as wall as glycosaminoglycans inhibit the enzymatic activity of human cathepsin G. FEBS Lett 2003, 537:23-29
11. Tardieu M, Gamby C, Avramoglou T, Jozefonvicz J, Barritault D: Derivatized dextrans mimic heparin as stabilizers, potentiators, and protectors of acidic or basic FGF. J Cell Physiol 1992, 150:194-203
12. Desgranges P, Barritault D, Caruelle JP, Tardieu M: Transmural endothelialization of vascular prostheses is regulated in vitro by fibroblast growth factor 2 and heparan-like molecule. Int J Artif Organs 1997, 20:589-598
13. Lafont J, Baroukh B, Berdal A, Colombier ML, Barritault D, Caruelle JP, Saffar JL: RGTA11, a new healing agent, triggers developmental events during healing of craniotomy defects in adult rat. Growth Factors 1998, 16:23-38
14. Desgranges P, Barbaud C, Caruelle JP, Barritault D, Gautron J: A substituted dextran enhances muscle fiber survival and regeneration in ischemic and denervated rat EDL muscle. EMBO J 1999, 13:761-766
15. Yamauchi H, Desgranges P, Lecerf P, Papy D, Tournaire MC, Moczar M, Loisance D, Barritault D: New agents for the treatment of infarcted myocardium. EMBO J 2000, 14:2133-2134
16. Gogly B, Groult N, Hornebeck W, Godeau G, Pellat B: Collagen zymography as a sensitive and specific technique for the determination of subpicogram levels of interstitial collagenase. Anal Biochem 1998, 255:211-216
17. Iki K, Tsutsumi M, Kido A, Sakitani H, Takahama M, Yoshimoto M, Motoyama M, Tatsumi K, Tsunoda T, Konishi Y: Expression of matrix metalloproteinase 2 (MMP-2), membrane-type 1 MMP and tissue inhibitor of metalloproteinase 2 and activation of proMMP-2 in pancreatic duct adenocarcinomas in hamsters treated with N-nitrosobis (2-oxopropyl)amine. Carcinogenesis 1999, 20:1323-1329
18. Sonis ST, Van Vugt AG, McDonald J, Dotoli E, Schwertschlag U, Szklut P, Keith J: Mitigating effects of interleukin 11 on consecutive courses of 5-fluorouracil-induced ulcerative mucositis in hamsters. Cytokine 1997, 9:605-612
19. Koliakos GG, Kouzi-Koliakos K, Furcht LT, Reger LA, Tsilibary EC: The binding of heparin to type IV collagen: domain specificity with identification of peptide sequences from the alpha 1(IV) and alpha 2(IV) which preferentially bind heparin. J Biol Chem 1989, 264:2313-2323
20. Battaglia C, Mayer U, Aumailley M, Timpl R: Basement-membrane heparan sulfate proteoglycan binds to laminin by its heparan sulfate chains and to nidogen by sites in the protein core. Eur J Biochem 1992, 208:359-366
21. Nakagami Y, Abe K, Nishiyama NL, Matsuki N: Laminin degradation by plasmin regulates long-term potentiation. J Neurosci 2000, 20: 2003-2010
22. Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S, Mignatti P: Control of type collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J 1997, 16:2319-2332
23. Monea S, Lehti K, Keski-Oja J, Mignatti P: Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J Cell Physiol 2002, 192:160-170
24. van den Steen PH, Opdenakker G, Wormald MR, Dwek RA, Rudd PM: Matrix remodelling enzymes, the protease cascade and glycosylation. Biochim Biophys Acta 2001, 1528:61-73
25. Meddahi A, Brée F, Papy-Garcia D, Gautron J, Barritault D: Pharmacological studies of RGTA11, a heparan sulfate mimetic polymer, efficient on muscle regeneration. J Biomed Mater Res 2002, 62:525-531
26. Erickson AC, Couchman JR: Still more complexity in mammalian basement membranes. J Histochem Cytochem 2000, 48:1291-1306
27. Kenagy RD, Nikkari ST, Welgus HG, Clowes AW: Heparin inhibits the induction of three metalloproteinases (stromelysin, 92 kD gelatinase, and collagenase) in primate arterial smooth muscle cells. J Clin Invest 1994, 93:1987-1993
28. Meddahi A, Benoit J, Ayoub N, Sézeur A, Barritault D: Heparin-like polymers derived from dextran enhance colonic anastomosis resistance to leakage. J Biomed Mater Res 1996, 31:293-297
29. Sonis ST, Van Vugt AG, Brien JP, Muska AD, Bruskin AM, Rose A, Haley JD: Transforming growth factor-beta 3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis. Oral Oncol 1997, 33:47-54
30. Farrell CL, Bready JV, Rex KL, Chen JN, DiPalma CR, Whitcomb KL, Yin S, Hill DC, Wiemann B, Starnes CO, Havill AM, Lu ZN, Aukerman SL, Pierce GF, Thomason A, Potten CS, Ulich TR, Lacey DL: Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 1998, 58: 933-939
31. Anastase-Ravion S, Blondin C, Cholley B, Haeffner-Cavaillon N, Castellot JJ, Letourneur D: Heparin inhibits lipopolysaccharide (LPS) binding to leukocytes and LPS-induced cytokine production. J Biomed Mater Res 2003, 66A:376-384
32. Dreizen S, Bodey GP, Brown LR: Opportunistic gram-negative bacillary infections in leukemia. Oral manifestations during myelosuppression. Postgrad Med 1974, 55:133-139